Aprea reported $37.8M in cash and expanded its WEE1 inhibitor trials, with cash runway extending into early 2028. Updated Phase 1 data is set for presentation at EORTC-NCI-AACR Symposium in November 2026.
Aprea reported $37.8M in cash and expanded its WEE1 inhibitor trials, with cash runway extending into early 2028. Updated Phase 1 data is set for presentation at EORTC-NCI-AACR Symposium in November 2026.